Legend Biotech (LEGN) has recently gained attention following its Q1 2026 financial results, which revealed a revenue of $305.1 million and a reduced net loss of $54.3 million. This marks an improvement in loss per share compared to the previous year, highlighting a positive shift in the company's financial trajectory.
Despite a challenging long-term performance, with a 55.77% decline over three years, recent market momentum is evident, as the stock has surged 54.47% in the past 90 days. Analysts suggest that this uptick may be indicative of market optimism regarding future growth, particularly in the realm of multiple myeloma therapies, which could see significant revenue acceleration as patient access expands through ongoing clinical trials.
The current market valuation positions Legend Biotech as potentially undervalued, with a fair value estimate of $57.24 against a closing price of $27.99. This disparity underscores the market's expectations for aggressive growth and rising profitability. However, analysts caution that the narrative could shift if the company's CARVYKTI treatment underperforms or if competition intensifies.
While the price-to-sales (P/S) ratio of 4.6x is below the average for U.S. biotechs, it remains above the fair ratio of 3.4x, suggesting a complex valuation landscape. Investors are advised to scrutinize the underlying assumptions driving these valuations, as well as to consider broader investment opportunities within the life sciences sector.